Tashfeen Mahmood, MD
Pulmonary Disease · Lake Charles, LANPI 1366676074
Payments from drug & device makers
What this record shows
The money is spread across several categories — education (44.4%), food and beverage and travel and lodging — rather than concentrated in one kind of arrangement. Intuitive Surgical accounts for 65.2% of it on its own, with 27 other manufacturers making up the rest. Reporting peaked in 2023 at $8,585 and has fallen 93.4% since, to $567 in 2025.
Across 155 payments — averaging $89.51 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Intuitive Surgical$9K
- Regeneron Healthcare Solutions, Inc.$2K
- Sanofi$593
- GSK$413
- AstraZeneca$274
- Mylan Specialty L.p.$219
- plus $1K from 22 others
What the payments were for
- Consulting fees$1,60212%
- Travel & lodging$2,49618%
- Food & beverage$3,56926%
- Education$6,16444%
- Gifts$430%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Intuitive Surgical | 20 | $9,050 |
| Regeneron Healthcare Solutions, Inc. | 12 | $1,917 |
| Sanofi | 20 | $593 |
| GSK | 24 | $413 |
| AstraZeneca | 15 | $274 |
| Mylan Specialty L.p. | 10 | $219 |
| Bayer | 9 | $189 |
| Siemens Medical Solutions USA, Inc. | 1 | $138 |
| Jazz Pharmaceuticals Inc. | 2 | $124 |
| Genentech USA, Inc. | 1 | $124 |
| Merck | 1 | $115 |
| Insmed, Inc. | 4 | $95 |
| Baxter Healthcare | 4 | $84 |
| ANI Pharmaceuticals, Inc. | 4 | $83 |
| Sunovion Pharmaceuticals Inc. | 11 | $77 |
| Grifols USA, LLC | 3 | $66 |
| Inspire Medical Systems, Inc. | 1 | $56 |
| Boehringer Ingelheim | 2 | $45 |
| Tactile Systems Technology Inc | 1 | $39 |
| Viatris Specialty LLC | 2 | $29 |
| Biomerieux Inc | 1 | $22 |
| Verona Pharma, Inc. | 1 | $21 |
| Lilly USA, LLC | 1 | $20 |
| Actelion Pharmaceuticals US, Inc. | 1 | $20 |
| Philips North America LLC | 1 | $20 |
| Shionogi Inc | 1 | $14 |
| Pfizer | 1 | $14 |
| Veran Medical Technologies, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$13,874 in reported general payments places this provider in the 85th percentile of 189 pulmonary disease providers in Louisiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 60 | $52,571 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 25 | $22,792 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 16 | $7,559 |
| Varenicline Tartrate | 32 | $3,198 |
| SymbicortBudesonide/Formoterol Fumarate | 13 | $2,897 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 48 | $1,321 |
| Roflumilast | 11 | $887 |
| Bupropion Hcl SrBupropion Hcl | 37 | $490 |
| Montelukast Sodium | 17 | $29 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Anoro Ellipta | $413 | $60,13076 claims |
| AstraZenecaBreztri Aerosphere, Symbicort | $274 | $25,68938 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 189 pulmonary disease providers in Louisiana.
Other pulmonary disease in Lake Charles
- Gary KohlerLake Charles$21K
- Luke WilliamsLake Charles$16K
- Robert BroussardLake Charles$15K
- Clifford CourvilleLake Charles$15K
- Andrea EspinozaHouma$655K
- Joseph LaskyNew Orleans$447K
- Hollis O NealBaton Rouge$418K
- Ramsy AbdelghaniNew Orleans$308K
- Juzar AliNew Orleans$216K
- Warren BotnickNatchitoches$213K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.